A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma

Oncotarget

Volumn 7, Issue 43, 2016, Pages 69991-69999

  Wang, Wen ^a,b,c,g   Zhang, Lu ^e   Wang, Zheng ^b,c,g   Yang, Fan ^b,c,g   Wang, Haoyuan ^f,g   Liang, Tingyu ^b,c,g   Wu, Fan ^c,d,g   Lan, Qing ^a   Wang, Jiangfei ^b,d,g   Zhao, Jizong ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^e SHANDONG UNIVERSITY   (China)

^f SOUTHERN MEDICAL UNIVERSITY   (China)

^g Chinese Glioma Cooperative Group (CGCG)   (China)

Author keywords

Glioblastoma; MGMT; Prognosis; RNA Seq; Signature

Indexed keywords

ANTINEOPLASTIC AGENT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETIC SCREENING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MGMT GENE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RNA SEQUENCE; SYNAPTIC TRANSMISSION; ADULT; AGED; BRAIN TUMOR; DNA METHYLATION; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TUMOR SUPPRESSOR PROTEINS;

EID: 84994291340     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11726     Document Type: Article

References (28)

1. Nikiforova MN, Hamilton RL. Molecular diagnostics of gliomas. Archives of pathology & laboratory medicine. 2011; 135:558-568.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996.
3. Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 2015; 38:E4.
4. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17:510-522.
5. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol. 2009; 117:653-656.
6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343:1350-1354.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, MirimanoffRO, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003.
8. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44-57.
9. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-15550.
10. Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle. 2003; 2:550-552.
11. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006; 25:6758-6780.
12. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006; 25:6680-6684.
13. Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB, Lee JR, Liu K. NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. The Journal of biological chemistry. 2012; 287:25530-25540.
14. Lee HY, Lee SY, Shin EH, Kim SD, Kim JM, Lee MS, Ryu SH, Bae YS. F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling. Biochemical and biophysical research communications. 2007; 359:985-990.
15. Devosse T, Guillabert A, D'Haene N, Berton A, De Nadai P, Noel S, Brait M, Franssen JD, Sozzani S, Salmon I, Parmentier M. Formyl peptide receptor-like 2 is expressed and functional in plasmacytoid dendritic cells, tissuespecific macrophage subpopulations, and eosinophils. Journal of immunology. 2009; 182:4974-4984.
16. Migeotte I, Riboldi E, Franssen JD, Gregoire F, Loison C, Wittamer V, Detheux M, Robberecht P, Costagliola S, Vassart G, Sozzani S, Parmentier M, Communi D. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. The Journal of experimental medicine. 2005; 201:83-93.
17. Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016; 86:2226-2234.
18. Hofer-Warbinek R, Schmid JA, Mayer H, Winsauer G, Orel L, Mueller B, Wiesner C, Binder BR, de Martin R. A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell death and differentiation. 2004; 11:1317-1325.
19. Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, Spugnini EP, Baldi A. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Experimental dermatology. 2005; 14:811-818.
20. Shang J, Yang F, Wang Y, Wang Y, Xue G, Mei Q, Wang F, Sun S. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. Journal of cellular biochemistry. 2014; 115:772-784.
21. Benedyk M, Sopalla C, Nacken W, Bode G, Melkonyan H, BanfiB, KerkhoffC. HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9 show increased NADPH oxidase and NF-kappaB activities. The Journal of investigative dermatology. 2007; 127:2001-2011.
22. Bergenfelz C, Gaber A, Allaoui R, Mehmeti M, Jirstrom K, Leanderson T, Leandersson K. S100A9 expressed in ER(-) PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. British journal of cancer. 2015; 113:1234-1243.
23. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Experimental cell research. 2006; 312:184-197.
24. Choi DK, Li ZJ, Chang IK, Yeo MK, Kim JM, Sohn KC, Im M, Seo YJ, Lee JH, Kim CD, Lee Y. Clinicopathological roles of S100A8 and S100A9 in cutaneous squamous cell carcinoma in vivo and in vitro. Archives of dermatological research. 2014; 306:489-496.
25. Wu R, Duan L, Cui F, Cao J, Xiang Y, Tang Y, Zhou L. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. Experimental cell research. 2015; 334:228-238.
26. Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget. 2015; 6:29285-29295. doi: 10.18632/oncotarget.4978.
27. Bao ZS, Li MY, Wang JY, Zhang CB, Wang HJ, Yan W, Liu YW, Zhang W, Chen L, Jiang T. Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. CNS neuroscience & therapeutics. 2014; 20:112-118.
28. Zhang CB, Zhu P, Yang P, Cai JQ, Wang ZL, Li QB, Bao ZS, Zhang W, Jiang T. Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget. 2015; 6:36643-36651. doi: 10.18632/oncotarget.5421.